Recent Updates
Recently added Catalysts
SRPT Negative Sentiment Score: 30/100

Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 – SRPT

Key Takeaway: Sarepta Therapeutics, Inc. is facing a class action lawsuit regarding alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025. The complaint alleges that the company's gene therapy ELEVIDYS has unreported safety risks and that trial protocols failed to detect severe side effects. As a result, the lawsuit claims that investors were misled about the therapy's safety and regulatory approval process. Investors have until August 25, 2025, to apply to become lead plaintiffs in the case.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Sarepta, alleging securities fraud.
  • The lawsuit claims that the company's gene therapy ELEVIDYS posed significant safety risks to patients, which were concealed.
  • There are concerns that severe side effects from ELEVIDYS treatment could halt trials and regulatory scrutiny.
  • The allegations suggest that the company misled investors regarding the safety and efficacy of their therapy.

Full Press Release Details

NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:
SRPT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.
WHAT'S NEXT? If you suffered a loss in Sarepta during the relevant time frame, you have until August 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the Sarepta Therapeutics lawsuit about?

The lawsuit addresses alleged securities fraud affecting Sarepta investors from June 22, 2023, to June 24, 2025.

What claims are made against Sarepta in the lawsuit?

The lawsuit alleges that Sarepta concealed safety risks of its gene therapy, ELEVIDYS.

What should Sarepta investors do if they lost money?

Investors may request to be appointed as lead plaintiff by August 25, 2025.

Are there fees for participating in the lawsuit?

There are no costs or obligations for class members to participate in the lawsuit.

Why choose Levi & Korsinsky for this case?

They have a strong track record and extensive experience in securities litigation.

Last updated: Aug 19, 2025